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Sphingolipids have garnered attention for their role in
insulin resistance and lipotoxic cell death. We have
developed transgenic mice inducibly expressing
acid ceramidase that display a reduction in ceram-
ides in adult mouse tissues. Hepatic overexpression
of acid ceramidase prevents hepatic steatosis and
prompts improvements in insulin action in liver
and adipose tissue upon exposure to high-fat
diet. Conversely, overexpression of acid ceramidase
within adipose tissue also prevents hepatic steatosis
and systemic insulin resistance. Induction of ceram-
idase activity in either tissue promotes a lowering of
hepatic ceramides and reduced activation of the
ceramide-activated protein kinase C isoform PKCz,
though the induction of ceramidase activity in the
adipocyte prompts more rapid resolution of hepatic
steatosis than overexpression of the enzyme directly
in the liver. Collectively, our observations suggest the
existence of a rapidly acting ‘‘cross-talk’’ between
liver and adipose tissue sphingolipids, critically regu-
lating glucose metabolism and hepatic lipid uptake.
INTRODUCTION
Numerous studies in humans and animals have shown that
hepatic steatosis is strongly associated with insulin resistance.
Mice challenged with a high-fat diet (HFD) develop severe insu-
lin resistance and hepatic steatosis (Birkenfeld and Shulman,
2014; Shimomura et al., 1999a, 1999b). However, the causal
relationship between hepatic steatosis and insulin resistance
is unclear and controversial. Murine models with altered hepat-
ic lipid storage (Monetti et al., 2007; Yu et al., 2005), mobiliza-
tion (Brown et al., 2010; Hoy et al., 2011; Minehira et al., 2008),
and oxidation (Monse´ne´go et al., 2012) all exhibit greatly
increased hepatic lipid accumulation without accompanying
insulin resistance. Conversely, alterations in hepatic insulin266 Cell Metabolism 22, 266–278, August 4, 2015 ª2015 Elsevier Incsignaling are sufficient to induce hepatic steatosis (Taniguchi
et al., 2005).
Ceramides are important members of the sphingolipid family
and are essential precursors for complex sphingolipids. A series
of studies have shown that increased ceramide levels in both
liver and plasma coincide with the development of liver dysfunc-
tion, hepatic insulin resistance, and steatosis in rodents (Ichi
et al., 2007; Xia et al., 2014; Yetukuri et al., 2007). Previous
work has identified the liver as a target of ceramide-induced in-
sulin resistance and inhibition of whole-body ceramide synthesis
reduces obesity-induced insulin resistance in rodents (Holland
et al., 2007). In particular, ceramides derived fromC16 fatty acids
appear to oppose insulin action most potently (Raichur et al.,
2014; Turpin et al., 2014). Breakdown of ceramides are initiated
by enzymes called ceramidases, which are categorized by ho-
mology and pH optima at which they can hydrolyze ceramides
into sphingosines and free fatty acids (Xia et al., 2014). The
anti-diabetic and anti-steatotic adipokine, adiponectin, rapidly
lowers hepatic ceramide content, thereby improving glucose ho-
meostasis through its receptor-associated ceramidase activity
(Holland et al., 2011). Similarly, overexpression of acid cerami-
dase in cultured cells prevents saturated fatty acids from impair-
ing insulin action in cultured C2C12 myotubes (Chavez et al.,
2003).
Previous studies on the role of sphingolipid biosynthetic
enzymes in systemic metabolism have employed constitutive
gain-of-function or loss-of-function models. However, the use-
fulness of these constitutivemodels has been limited by complex
phenotypes due to compensatory mechanisms and develop-
mental issues. To further investigate the physiological effects
of an acute increase in ceramidase activity in a tissue-specific
manner, we have developed transgenic mice that express acid
ceramidase under the control of a tetracycline response element
cell type-specifically. This allows us to induce ceramide deacy-
lation in response to doxycycline exposure, resulting in the
degradation of ceramides made within the cell or following up-
take from serum. These models reveal profound improvements
in hepatic steatosis and glucose metabolism with strong evi-
dence for interorgan cross-talk as sphingolipids are shunted
back and forth between liver and adipose. Thus, this system
enables us to probe the impact of a genetically induced, acute.
change in ceramide levels on local and systemic insulin
sensitivity.
RESULTS
Overexpression of Acid Ceramidase in the Liver
Reduces Hepatic Ceramide Levels and Improves
Hepatic and Adipose Insulin Sensitivity
Myriocin, an inhibitor of de novo ceramide synthesis, also
robustly protects against hepatic steatosis when wild-type
mice are maintained on a HFD (Figure S1A). To disrupt the
over-accumulation of ceramides in the liver, we generated an
inducible, liver-specific acid ceramidase transgenic (Alb-AC)
mouse, which combines three transgenic lines: the albumin
promoter-driven Cre line, a transgenic line carrying a Rosa26
promoter-driven loxP-stop-loxP-reverse tetracycline-controlled
transactivator (rtTA) gene, and a Tet-responsive mouse acid ce-
ramidase transgenic line (TRE-AC) (FigureS1B). In theabsenceof
doxycycline, there is only a low level of endogenous acid ceram-
idase message expressed when using a primer set recognizing
both transgenic and endogenous acid ceramidase sequences.
Upon treatment with doxycycline, AC gene expression in the tri-
ple transgenics reaches approximately four times the levels seen
inwild-type (WT) littermates. The overexpression is liver-specific,
as it is not detected in any other tissues (Figure S1C). The in-
crease in hepatic AC mRNA levels resulted in a 3-fold increase
in acid ceramidase enzyme activity in the liver (Figure S1D).
Serum ceramidase activity was not changed between WT and
Alb-AC mice after doxycycline induction (Figure S1E).
We challenged the WT and Alb-AC mice with a HFD (60% cal-
ories from fat) containing 200 mg/kg doxycycline (HFD-dox).
After 8 weeks of HFD-dox exposure, wild-type mice showed a
2.4-fold increase in hepatic ceramides compared to chow-fed
controls (Figure S1F). Alb-AC mice showed a significant reduc-
tion in C16:0 and C18:0 hepatic ceramide species (Figure 1A). In
parallel, a significant lowering of C16:0 and C18:0 ceramide spe-
cies was also observed in the serum (Figure 1A). Interestingly,
although levels of liver sphingoid species did not change signif-
icantly compared to WT except for the levels of sphingosine,
serum sphingoid species exhibited a sharp decline compared
to WT (Figure S1G). Since past evidence showing the negative
correlation between the signaling lipid diacyglycerol (DAG) and
hepatic steatosis and insulin resistance (Shulman, 2014), we
also measured hepatic levels of DAGs. Surprisingly, we found
that levels of DAG in the liver were significantly higher in our
Alb-AC mice compared to WT (Figure 1B). Transcriptionally,
we foundmRNA levels of DGAT1 decreased to 30%ofWT, while
levels of DGAT2 increased to 5-fold above WT levels (Fig-
ure S1H). Serum levels of DAGs were comparable between WT
and Alb-AC mice (Figure 1B).
We exposed Alb-AC and WT littermate control mice to HFD-
dox for 8 weeks. We observed similar weight gain curves for
the Alb-AC and WT mice and comparable body weights at the
end of the 8 weeks of HFD-dox exposure (Figure S1I). However,
compared to WT controls, Alb-AC mice exhibited significantly
reduced blood glucose levels during the oral glucose tolerance
test (OGTT) (Figure 1C), indicating an improvement in systemic
glucose tolerance. Additionally, the plasma insulin levels during
the OGTT were also markedly lower in the Alb-AC mice (Fig-Celure 1D). Furthermore, HFD-dox-fed Alb-AC mice also had sub-
stantially decreased blood glucose levels after insulin injection
during an insulin tolerance test (ITT) (Figure 1E), suggesting
enhanced insulin sensitivity.
We performed hyperinsulinemic-euglycemic clamp studies.
The glucose infusion rate needed to maintain euglycemic condi-
tions (150 mg/dl) was increased in Alb-AC mice compared to
their littermate controls (Figure 1F, left panel), demonstrating
that whole-body insulin sensitivity is improved. Whole body
glucose disposal was not altered (Figure S1J), suggesting mini-
mal effects on muscle insulin action. There were no significant
changes in lipolysis between WT and Alb-AC mice under
clamped or under insulinopenic conditions where insulin-
induced suppression of lipolysis is more pronounced (Table 1;
Figure S1K). Hepatic glucose production under hyperinsulinemic
clamp conditions was suppressed more efficiently in Alb-AC
mice (Figure 1F, right panel). Specifically, hyperinsulinemic
clamp conditions suppressed hepatic glucose production of
Alb-AC mice by 47% compared to 15% of WT mice (Fig-
ure S1L). Insulin signaling in the liver and adipose tissue was
assessed by insulin-stimulated phosphorylation of Akt. p-Akt
levels were greatly increased in the liver of transgenic animals.
Moreover, even though the increase in ceramidase activity is
restricted to hepatocytes, insulin-stimulated p-Akt in gonadal
adipose tissue was also elevated (Figure 1G). Consistent with
these observations, 2-deoxyglucose uptake during clamped
hyperinsulinemic conditions showed that the gonadal (gWAT),
subcutaneous (sWAT), and mesenteric (mWAT) fat pads of
Alb-AC mice had increased 2-deoxyglucose uptake compared
to WT (Figure 1H). Differences in glucose disposal and glucose
production could not be explained by minimal differences in
body weight or glucose or insulin levels during the clamped state
(Table 1).
Overexpression of Acid Ceramidase in the Hepatocyte
Prevents HFD-Mediated Hepatic Lipid Accumulation
and Attenuates Adipose Tissue Inflammation and
Fibrosis
While the HFD causes a marked increase in the liver weights of
both Alb-AC and WT mice, the livers from Alb-AC mice are qual-
itatively smaller and less lipid-laden compared to WT (Figure 2A,
left). The weights of the Alb-ACmouse livers were lower than that
of WT mice, even after normalizing to body weight (Figure 2A,
right). Histologically, the Alb-AC liver exhibited substantially
less lipid accumulation compared to that of the WT control
(Figure 2B, left). Mirroring the histological findings, Alb-AC
mice exhibited almost a 3-fold decrease in hepatic triglyceride
(TG) content compared to WT mice (Figure 2B, right).
In addition, we performed a triglyceride clearance test by gav-
aging a lipid emulsion (20% Intralipid) to both Alb-AC and WT
mice. Surprisingly, the Alb-AC mice peaked at higher levels
and had a lower rate of triglyceride clearance compared to WT
(Figure 2C). To determine whether AC overexpression affected
hepatic VLDL production, mice were fasted for 3 hr followed
by intravenous injection of tyloxapol, a potent inhibitor of capil-
lary lipoprotein lipase. Alb-AC mice had higher plasma TG levels
compared toWTmice 2 hr post-injection, indicating that the rate
of VLDL production in Alb-ACmice is markedly higher compared
to WT mice (Figure 2D).l Metabolism 22, 266–278, August 4, 2015 ª2015 Elsevier Inc. 267
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Figure 1. Inducible Liver-Specific Overexpression of Acid Ceramidase Results in Significantly Reduced C16:0 Ceramide Species in the Liver
and Improved Total Body Glucose Homeostasis and Insulin Sensitivity under HFD Feeding
(A) Analysis of liver and serum ceramide species from Alb-AC mice and WT littermates.
(B) Analysis of liver and serum diacylglycerol (DAG) levels in Alb-AC mice and control littermates.
(C) Circulating glucose levels were measured during an oral glucose tolerance test (OGTT) (2.5 g/kg glucose per oral gavage).
(D) Serum insulin levels during the OGTT were quantified via ELISA.
(E) Circulating glucose levels measured during an insulin tolerance test (ITT) (0.75 U/kg).
(F) Glucose infusion rates (left) and hepatic glucose output (right) during hyperinsulinemic-euglycemic clamp experiments performed on conscious unrestrained
10-week-old WT and Alb-AC males.
(G) Representative immunoblots of phosphorylated and total Akt of insulin-stimulated WT and Alb-AC mice, shown in triplicate.
(H) 2-Deoxyglucose uptake quantification on conscious unrestrained 10-week-old WT mice and Alb-AC males. All samples are from Alb-AC mice and
WT littermates after 8 weeks of HFD-dox challenge (n = 6), unless specified otherwise. *p < 0.05 by Student’s t test.
See also Figure S1.We intravenously injected a 3H-triolein tracer into Alb-AC
and WT mice that allows for assessments of lipid storage
and b oxidation rates in different tissues. Alb-AC mice have a
reduced lipid uptake in the liver compared to WT mice; concur-
rent increases were observed in the gonadal and brown fat pads
(Figure 2E). Lipid oxidation was not significantly altered (Fig-
ure S2A). In order to determine how overexpression of AC ame-
liorates hepatic steatosis, we performed microarray analyses on
liver tissues specifically at 2 weeks post-induction and then
at 2 months post-induction of the AC transgene in the liver. A
reduction of genes in fatty acid (FA) synthesis and uptake path-
ways was evident. qPCR analyses confirmed the reduction in FA
synthesis genes (ACC, FAS, Scd-1, Elolv5, and SREBP-1a) and
FA uptake genes (CD36, FATP2, FATP5, L-FABP) by the end of
week 8 (Figures S2B and S2C). Surprisingly, qPCR of the fatty268 Cell Metabolism 22, 266–278, August 4, 2015 ª2015 Elsevier Incacid synthesis genes and fatty acid uptake genes in gWAT
showed a corresponding increase during this same period (Fig-
ures S2B and S2C).
A noticeable observation was the differences in fat pad dis-
tribution in Alb-AC mice compared to WTs when challenged
with HFD-dox. Alb-AC gWAT was substantially larger than
the corresponding pads in WT’s after HFD-dox challenge
when normalized to body weight, while the mWAT of Alb-AC
was relatively smaller than its counterpart in WT littermates
(Figures S2D and S2E). Furthermore, whole body NMR data
show that the overall composition of fat and lean mass in
Alb-AC and WT mice are comparable (Figure S2F), thus sug-
gesting that changes in fat pad weights are the result of redis-
tribution rather than an overall increase or decrease of overall
adipose tissue mass..
Table 1. Metabolic Parameters before and during Hyperinsulinemic-Euglycemic Clamp Study in WT and AC Transgenics
Body
Weight (g)
Basal Clamped
Plasma
Glucose
(mg/dl)
Plasma
Insulin
(ng/ml)
Plasma
NEFA
(mmol/l)
Plasma
Glycerol
(mg/ml)
Plasma
Glucose
(mg/dl)
Plasma
Insulin
(ng/ml)
Plasma
NEFA
(mmol/l)
Plasma
Glycerol
(mg/ml)
WT 49.4 ± 1.8 208.2 ± 7.8 0.87 ± 0.13 0.47 ± 0.06 0.41 ± 0.04 177.4 ± 5.1 3.58 ± 0.47 0.33 ± 0.06 0.47 ± 0.11
Alb-AC 48.8 ± 2.0 191 ± 3.9 0.83 ± 0.13 0.42 ± 0.03 0.32 ± 0.02 168 ± 6.5 4.2 ± 0.72 0.27 ± 0.07 0.38 ± 0.13
WT 30.8 ± 1.6 207 ± 2.4 0.98 ± 0.1 0.51 ± 0.08 0.59 ± 0.15 153.9 ± 4.6 3.4 ± 0.61 0.51 ± 0.06 0.41 ± 0.1
Art-AC 30.9 ± 1.06 174.2 ± 23.3 0.66 ± 0.16 0.42 ± 0.04 0.38 ± 0.09 142.7 ± 3.5 3.4 ± 0.5 0.34 ± 0.08 0.36 ± 0.09We evaluated gonadal adipose tissue for histological dif-
ferences (Figure 2F). While WT mice on HFD-dox displayed
crown-like structures characteristic of immune infiltration,
Alb-AC fat pads showed far fewer signs of inflammation.
Mac-2 immunohistochemistry staining confirmed that Alb-AC
fat pads had greatly reduced levels of infiltrated macrophages
compared to those of WT. In addition, we found markedly less
fibrosis in the fat pads of Alb-AC compared to their WT counter-
parts, as determined by trichrome staining (Figure 2F). Expres-
sion of inflammatory cytokines such as TNF-a, IL-6, and IL-10
were substantially reduced in the gWAT of Alb-AC mice (Fig-
ure S2G). Furthermore, fibrosis markers such as Col1a, Col3a,
and Col6a1 were also lower in the gWAT of Alb-AC mice
compared toWT (Figure S2H).We examined the levels of ceram-
ides in the gWAT of HFD-dox-fed Alb-AC and WT mice and
found that dihydro-ceramides and hexosyl-ceramide species
to be significantly lowered in Alb-AC mice after HFD-dox chal-
lenge compared to WT controls, while other ceramide species
remained unaltered (Figure 2G). Furthermore, there are no signif-
icant alterations in specific chain lengths of gWAT ceramides
(Figure S2I). gWAT sphingoid species levels, especially sphingo-
sine and sphinganine, were also significantly lowered in Alb-AC
mice compared to WT (Figure 2H). Ceramide synthesis pathway
genes (SPT2, SK1, CerS6) were found to be significantly reduced
in the gWAT of Alb-AC mice compared to WT at the end of
8 weeks of HFD-dox feeding (Figure S2J). By contrast, examina-
tion by qPCR of the genes in the ceramide synthesis pathway
in the Alb-AC liver showed a profound increase in several cer-
amide synthase (CerS) genes including CerS2, CerS5, and
CerS6. In contrast, CerS1 expression was significantly reduced
(Figure S2J).
Acid Ceramidase Overexpression in White Adipose
Tissue Improves Glucose Metabolism
By crossing the Tet-responsive acid ceramidase transgenic line
(TRE-AC) with an adiponectin-rtTA transgenic allele (Art) we
were able to achieve inducible overexpression of acid cerami-
dase (Art-AC) within multiple WAT depots (Figure S3A). Upon
doxycycline induction, AC overexpression is achieved exclu-
sively in the fat pads and remains unchanged in other tissues,
such as the liver (Figure S3B). In the absence of doxycycline,
overexpression was not detected, but acid ceramidase expres-
sion rose 3.5-fold following exposure to doxycycline in the
diet (200 mg/kg, 10 days, Figure S3C). This corresponded to a
1.8-, 1.3-, and 3.7-fold increase in acid ceramidase activity in
sWAT, gWAT, and mWAT, respectively, without alterations in
hepatic ceramidase activity (Figure S3D). Furthermore, serumCelceramidase activity in WT and Art-AC were not significantly
altered (Figure S3E). The lack of ceramide hydrolysis was further
confirmed with C17 ceramide, showing no alterations in hepatic
ceramidase activity (Figure S3F). On a doxycycline-enriched
chow diet, several ceramide subspecies were significantly
reduced in mWAT, while total ceramides were significantly
decreased in the liver (Figures S3G and S3H). Concomitant
decreases in fasting glucose and glucose excursion during oral
glucose tolerance tests were evident (Figure S3I) without any
changes in body weight (34.4 ± 3.1 g versus 32.7 ± 3.3 g for
wild-type and Art-AC, respectively).
Art-AC transgenic mice have a marked ability to maintain
normal glucose homeostasis on HFD. Total ceramides were
reduced in mesenteric (67%), gonadal (40%), and subcutaneous
(30%) fat pads, with C16 and C18 ceramides showing the most
consistent and robust changes (Figure 3A). Serum sphingolipid
species were also altered (Figure 3B). Specifically, serum levels
of C20:0 ceramides were reduced to 42% of WT levels (Fig-
ure S3J). Glucose levels were lower during the fasted state and
following an oral glucose challenge (Figure 3C), while insulin
levels remained markedly lower during fasting and 15 min
following glucose administration (Figure 3D). Improvements in
insulin sensitivity were confirmed by the enhanced lowering of
glucose upon insulin administration (Figure 3E) and occurred
without changes in body weight (40.0 ± 5.0 versus 38.4 ± 6.1
for wild-type and Art-AC, respectively). The improvements in
whole-body glucose homeostasis and insulin sensitivity could
hardly be explained by the relatively minor contribution of
adipose to glucose disposal. To address this more specif-
ically, we performed hyperinsulinemic-euglycemic clamps. The
glucose infusion rate required to maintain euglycemia wasmark-
edly higher in Art-AC transgenic mice, confirming improvements
in whole body insulin sensitivity (Figure 3F). The kinetics of
3H-glucose disposal were not altered, suggesting negligible
changes in insulin-stimulated glucose disposal by muscle (Fig-
ure S3K). Rather, Art-AC transgenic mice showed improvements
in the ability of insulin to suppress endogenous glucose produc-
tion (Figure 3G). Specifically, endogenous glucose production
was suppressed by 60% in Art-AC compared to 15% in
WT (Figure S3L). These improvements in insulin sensitivity could
not be explained by changes in body weight, circulating insulin
during the clamped state, or variations in the achieved glucose
concentrations during the clamped state (Table 1). Furthermore,
there were no significant changes in lipolysis between WT and
Art-ACmice under clamped or insulinopenic conditions (Table 1;
Figure S3M). Enhanced insulin-stimulated phosphorylation
of Akt was present in livers of these mice 30 min after insulinl Metabolism 22, 266–278, August 4, 2015 ª2015 Elsevier Inc. 269
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Figure 2. Liver-Specific Overexpression of Acid Ceramidase Significantly Reduces Hepatic Lipid Accumulation and Improves Adipose
Tissue Metabolic Health when Challenged with HFD
(A) A representative gross image of WT and Alb-AC livers. Bar graphs on the right represent the mass of the liver normalized to the total body weight of the mice.
(B) Representative H&E-stained images of WT and Alb-AC livers. Bar graphs on the right represent quantification of liver triglyceride levels.
(C) Circulating triglyceride (TG) levels were measured during an oral TG clearance test (20% intralipid, 15 ml/g body weight; single gavage) in Alb-AC mice and
WT littermate controls.
(D) Circulating triglyceride levels and the rate of hepatic VLDL export were measured following intravenous injection of tyloxapol (500 mg/kg) to inhibit plasma
VLDL clearance in Alb-AC mice and WT littermate controls.
(E) Total 3H-triolein lipid-uptake per tissue in WT and Alb-AC males at 15 min after injection (2 mCi per mouse in 100 ml of 5% intralipid, single tail-vein injection).
(F) Representative images of H&E, Mac-2, and trichrome staining of WT and Alb-AC gonadal fat pads.
(G) Total WAT ceramide species levels were quantified by tandem MS/MS.
(H) Total WAT sphingoid species levels were quantified by tandem MS/MS. All samples are from Alb-AC mice and WT littermates after 8 weeks of HFD-dox
challenge (n = 6), unless specified otherwise. *p < 0.05, ***p < 0.001 by Student’s t test.
See also Figure S2.stimulation (Figure 3H). Lowering ceramides in adipose also
enhanced insulin-stimulated phosphorylation of Akt in gonadal
fat pads, while changes in total Akt expression were not altered
in either tissue (Figure 3H). The rate of 2-deoxyglucose uptake
doubled in gonadal, mesenteric, and subcutaneous fat of Art-AC
transgenic mice (Figure 3I).
Acid Ceramidase Overexpression in White Adipose
Tissue Improves Hepatic Lipid Accumulation
We evaluated gonadal adipose tissue for histological differences
(Figure 4A). While WT mice on HFD-dox displayed crown-like
structures characteristic of immune infiltration, Art-AC fat pads
showed far fewer signs of inflammation. Mac-2 immunohisto-
chemistry staining confirmed that Art-AC fat pads had greatly
reduced levels of infiltrated macrophages compared to those270 Cell Metabolism 22, 266–278, August 4, 2015 ª2015 Elsevier Incof WT. In addition, we found markedly less fibrosis in the fat
pads of Art-AC compared to their WT counterparts, as deter-
mined by trichrome staining (Figure 4A). Correspondingly,
mRNA levels of TNF-a and pro-fibrotic genes (Col1a1, Col3a1,
Col6a1) were found to be notably lowered in WAT compared
to WT (Figure S4A).
Considering the fact that overexpression of AC in the liver
resulted in improvements in adipose tissue metabolic health,
we wanted to examine if the reverse is also true. Dissection of
the livers of the Art-AC transgenic mice clearly revealed less
steatotic livers, judged by both overall appearance and color
(Figure 4B, left). Hepatomegaly caused by a HFD is diminished
by transgene overexpression in adipose tissue (Figure 4B, right).
Lowering of hepatic triglyceride content was also evident histo-
logically (Figure 4C, left). Transgene overexpression in adipose.
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Figure 3. Inducible Adipose-Specific Overexpression of Acid Ceramidase Results in Ceramide Species in the Adipose and Improved Total
Body Glucose Homeostasis and Insulin Sensitivity under HFD Feeding
(A) Analysis of ceramide species of the indicated chain lengths from mesenteric (m), gonadal (g), and subcutaneous (s) fat pads from Art-AC mice and
WT littermates.
(B) Analysis of total ceramide and sphingoid species from serum of Art-AC and WT littermates.
(C) Circulating glucose levels were measured during an oral glucose tolerance test (OGTT) (2.5 g/kg glucose per oral gavage).
(D) Serum insulin levels before and 15 min after oral glucose.
(E) Circulating glucose levels measured during an insulin tolerance test (ITT) (0.75 U/kg).
(F) Glucose infusion rates during hyperinsulinemic-euglycemic clamp experiments performed on conscious unrestrained 14-week-old WT and Art-AC males
(n = 6 mice).
(G) Hepatic glucose efflux during hyperinsulinemic-euglycemic clamp experiments performed on conscious unrestrained 14-week-old WT and Art-AC males
(n = 6 mice).
(H) Representative immunoblots of phosphorylated and total Akt of insulin-stimulated livers and gWAT of WT and Art-AC mice, shown in triplicate.
(I) 2-Deoxyglucose uptake into fat pads of WT mice and Art-AC mice was assessed during the hyperinsulinemic-euglycemic state (n = 6 per group). All samples
are from Art-AC mice and WT littermates after 8 weeks of HFD –dox challenge (n = 6–8 per group). *p < 0.05, **p < 0.01, ***p < 0.001 by Student’s t test.
See also Figure S3.tissue decreased hepatic triglyceride accumulation on chow diet
by 45% (Figure S4B) and caused a 57% decrease in hepatic tri-
glyceride while on HFD (Figure 4C, right).
We subsequently evaluated lipid metabolism in more detail.
Neither fatty acids (Table 1) nor serum triglycerides (Figure 4D)
were different during the basal state. During hyperinsulinemic
clamps, Art-ACmice showed a trend toward improved suppres-Celsion of lipolysis (p = 0.06), as serum fatty acids trended lower in
Art-AC transgenic mice during the clamped state (Table 1). By
contrast, no changes in glycerol were apparent in the clamped
state. Following lipid gavage, the triglyceride clearance was
not different between WT and Art-AC transgenic mice (Fig-
ure 4D). Hepatic secretion of triglyceride was not affected by
adipose-restricted expression of acid ceramidase (Figure 4E).l Metabolism 22, 266–278, August 4, 2015 ª2015 Elsevier Inc. 271
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Figure 4. Adipose-Specific Overexpression of Acid Ceramidase Significantly Reduces Hepatic Lipid Accumulation and Improves Adipose
Tissue Metabolic Health when Challenged with HFD
(A) Representative images of H&E, Mac-2, and trichrome staining of WT and Art-AC gonadal fat pads.
(B) A representative gross image of WT and Art-AC livers. Bar graphs on the right represent the mass of the liver normalized to the total body weight of the mice.
(C) Representative H&E-stained images of WT and Art-AC livers. Bar graphs on the right represent biochemical quantification of liver triglyceride levels.
(D) Circulating triglyceride (TG) levels were measured during an oral TG clearance test (20% intralipid, 15 ml/g body weight; single gavage) in Art-ACmice andWT
littermate controls.
(E) Circulating triglyceride levels and the rate of hepatic VLDL export were measured following intravenous injection of tyloxapol (500 mg/kg) to inhibit plasma
VLDL clearance in Art-AC mice and WT littermate controls.
(F) Total 3H-triolein lipid-uptake per tissue in WT and Art-AC males 15 min after injection.
(G) Liver ceramide species and total ceramides were quantified and presented relative to WT levels of the same lipid species. All samples are from Art-AC mice
and WT littermates after 8 weeks of HFD-dox challenge (n = 6–10 per group). *p < 0.05 by Student’s t test.
See also Figure S4.In a complimentary approach, uptake of tritiated oleate was not
significantly altered in any of the fat pads evaluated following an
intravenous bolus of 3H-Triolein (Figure 4F). Lipid oxidation was
not altered in any of the tissues evaluated (Figure S4C). Unlike
adipose tissues, livers of transgenic mice displayed a 3.8-fold
decrease in lipid uptake (Figure 4F). Furthermore, levels of
C16:0 and C18:0 ceramide species were also markedly lower in
Art-AC compared to WT (Figure 4G). Hepatic diacylglycerols
were not significantly altered (Figure S4D).
Adipose-Specific Acid Ceramidase Reverses Insulin
Resistance and Hepatic Steatosis More Rapidly Than
Liver-Specific Ceramidase Induction
To determine whether the induction of AC in the liver or adipose
is able to reverse impairments in total body glucose metabolism
and rescue hepatic steatosis, Alb-AC, Art-AC, and WT mice272 Cell Metabolism 22, 266–278, August 4, 2015 ª2015 Elsevier Incwere first fed a doxycycline-free HFD for 2 months to facilitate
the development of hepatic steatosis prior to transgene induc-
tion. At the end of the 2 months, diets were switched to HFD-
dox to induce AC overexpression. Approximately 1 month after
transgene induction in the liver, we found C16:0 and C18:0 cer-
amide levels to be appreciably lowered along with concurrent
improvements in insulin signaling, as indicated by increased
phosphorylation of Akt (Figures 5A and 5B). Furthermore, he-
patic lipid accumulation was significantly lowered 4 weeks after
inducing overexpression of the transgene in the liver (Figure 5C).
An insulin tolerance test does not reveal any changes 3 days
post-induction of AC in the liver (Figure 5D). Our data not only
showed that the effects of the transgene take1 month to result
in significant physiological effects, but also that the local overex-
pression of AC in the liver can rescue livers with severe steatosis
after the steatosis has fully developed..
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Figure 5. Induction of Acid Ceramidase Significantly Improves Insulin Signaling and Rescues Hepatic Steatosis in Mice with Diet-Induced
Obesity
All mice were maintained on high-fat diets for 8 weeks prior to treatment with doxycycline.
(A) Liver ceramide species levels were quantified by tandem MS/MS for mice at pre-Dox treatment, 2 weeks, 4 weeks, and 8 weeks post-Dox treatment (n = 4
at each time).
(B) Representative immunoblots of phosphorylated and total Akt from liver of insulin-stimulated WT and Alb-ACmice at pre-Dox treatment, at 2 weeks, 4 weeks,
and 8 weeks post-Dox treatment (n = 4 at each time).
(C) Liver triglycerides were quantified at different time points before or after Dox treatment (n = 4 at each time).
(D) Circulating glucose levels measured during an insulin tolerance test (ITT) (0.75 U/kg) 3 days after HFD-dox treatment (n = 4).
(E) Ceramides were quantified from liver of WT and Art-ACmice at pre-Dox treatment, 3 days, 14 days, and 28 days of doxycycline treatment (n = 5 at each time).
(F) Representative immunoblots of phosphorylated and total Akt from liver of insulin-stimulated WT and Art-AC mice at pre-Dox treatment, at 24 hr, and 72 hr
post-Dox treatment (n = 4 at each time).
(G) Liver triglycerides were biochemically measured before and at the indicated time points after doxycycline addition to the diet in WT and Art-ACmice (n = 6–10
at each time).
(H) Insulin tolerance tests were performed 3 days after doxycycline treatments in WT and AC-Art littermates (n = 5). *p < 0.05 by Student’s t test.Overexpression of ACwithin the adipocyte offers amuchmore
rapid rescue of insulin resistance and hepatic steatosis. C16 and
C18 hepatic ceramides are substantially decreased within
3 days of treatment (Figure 5E). Western blotting for p-Akt in
the liver of Art-AC mice shows improvements in p-Akt levels
upon insulin administration within as short as 3 days post-induc-
tion of AC (Figure 5F). Within 3 days of transgene activation in the
adipocyte, hepatic triglyceride content is lower and continues to
improve substantially throughout the 4-week doxycycline treat-
ment (Figure 5G). Remarkably, insulin-stimulated lowering of
blood glucose is improved compared to wild-type littermates
during insulin tolerance tests after just 3 days (Figure 5H). Collec-
tively, these data show the ability of ceramidase to overcome
previously established metabolic perturbations promoted by
diet-induced obesity, with slightly different kinetics depending
on whether we express AC in hepatocytes or in adipocytes.
Ceramides Influence Hepatic Lipid Uptake via PKCz–
Mediated Influence on CD36, and AC Downregulates
Lipid Uptake and Fatty Acid Synthesis Genes in the Liver
Livers from Alb-AC and Art-AC mice showed comparable de-
creases in expression of CD36 as compared to WT littermatesCel(Figure 6A). The relative abundance of hepatic CD36 protein
was also clearly reduced in both Art-AC and Alb-AC transgenic
mice (Figure 6B).
In addition to their roles as mediators of ceramide-induced in-
sulin resistance, atypical PKCs have been noted to relay critical
signals for lipogenesis and lipid uptake (Luiken et al., 2009; Sajan
et al., 2004, 2009; Taniguchi et al., 2006). Consistent with this,
aPKC expression (Figure 6C) and activity (Figure 6D) were
decreased in the livers of Alb-AC and Art-AC transgenic mice.
Furthermore, aPKC activity was significantly lowered in Art-AC
mice after only three days of doxycycline treatment (Figure S5A).
Since aPKCs can play a permissive role in CD36 translocation,
we evaluated the propensity for ceramide to facilitate lipid
uptake. In cultured H4IIe hepatocyte cells, a 1 hr pre-incubation
with the short chain ceramide analog C2-ceramidewas sufficient
to stimulate a 63% increase in palmitate uptake (Figure 6E) and
markedly enhanced aPKC activity (Figure 6F). Incubation of
cells with C2-ceramide yielded the same lipid uptake results
as when cells were pretreated with palmitate, which promotes
the formation of endogenous ceramides intracellularly (Fig-
ure S5B). To evaluate the requirement for aPKC in this effect,
we blocked aPKC activation by including a myristoylated PKCzl Metabolism 22, 266–278, August 4, 2015 ª2015 Elsevier Inc. 273
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Figure 6. Ceramides Facilitate Lipid Uptake by Mechanisms Involving Activation of PKCz and CD36
(A) Relative abundance of CD36 mRNA was assessed by qPCR from livers of WT, Alb-AC, and Art-AC mice following 8 weeks of HFD-dox.
(B) Hepatic expression of CD36 was assessed by western blotting, and representative results are shown in duplicate.
(C) Hepatic expression of PKCz were assessed by western blotting, and representative results are shown in duplicate.
(D) PKCz activity was assessed from livers of WT, Alb-AC, and Art-AC mice following 8 weeks of HFD-dox.
(legend continued on next page)
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pseudosubstrate inhibitor that completely prevented ceramide-
induced lipid uptake, as it prevented ceramide from acti-
vating PKCz (Figures 6E and 6F). To confirm this genetically,
we achieved overexpression of dominant-negative (dn)PKCz or
expression of constitutively active (ca)PKCz via transient trans-
fection. Following overexpression with dnPKCz, C2-ceramide
failed to stimulate PKCz activity in cells expressing dnPKCz,
and it also failed to stimulate lipid uptake. By contrast, overex-
pression of (ca)PKCz stimulated PKCz activity to the same
degree as C2-ceramide and was sufficient to increase palmitate
uptake, but could not be further enhanced by ceramide addition
(Figures 6E and 6F). Immunohistological staining of H4IIe cells
grown in glass bottom culture dishes showed that treatment
with C2-ceramide resulted in both an increase in CD36 translo-
cation to the membrane as judged by an increase in plasma
membrane localized intensity of CD36 signal compared to cells
treated with DMSO (Figure 6G). Following overexpression with
dnPKCz, C2-ceramide failed to stimulate CD36 translocation to
the membrane, as there is no change between plasma mem-
brane localized intensity of CD36 signal between C2-ceramide
and DMSO-treated cells (Figure 6G). Conversely, overexpres-
sion of (ca)PKCz in H4IIe cells resulted in an increase in CD36
translocation to the membrane, treatment with C2-ceramide of
the (ca)PKCz transfected cells did not increase the signal inten-
sity of CD36 in the plasma membrane (Figure 6G). As sphingo-
sine, a byproduct of the ceramidase reaction, is a known inhibitor
of multiple PKCs, we also evaluated the propensity for sphingo-
sine to alter aPKC activation and lipid uptake. Incubation of
H4IIe cells with sphingosine, rather than ceramide impaired
aPKC activity (Figure S5C) and diminished palmitate uptake
(Figure S5D).
To confirm our findings in vivo, we first induced hepatic stea-
tosis in Alb-AC and Art-ACmice and their littermate controls with
4 weeks of HFD feeding. We subsequently injected both the
transgenic and WT mice with either PBS or 2-acetyl-1,3-cyclo-
pentanedione (ACPD), a known PKCz inhibitor demonstrated in
previous studies to effectively reduce PKCz activity (Sajan
et al., 2015), and compared the results with WT and transgenic
mice fed a doxycycline diet. For the Alb-AC cohort, we found
that injection of ACPD for 1 month in WT and Alb-AC mice re-
sulted in the same improvements in insulin sensitivity and reduc-
tion in hepatic lipid accumulation as Alb-AC mice fed a HFD-dox
diet for the same time (Figures 6H and 6I). Similarly, injection of
ACPD in Art-AC and WT mice resulted in a more rapid improve-
ment in insulin sensitivity and hepatic lipid accumulation after
three days of injection, mimicking the effects of three days of
HFD-dox diet in Art-AC mice (Figures 6H and 6I).(E and F) Following transfection with GFP, dnPKCz, or caPKCz H4IIe hepatocytes
assessment of 3H-palmitate uptake. Myristoylated PKCz pseudosubstrate inhibito
(n = 4–8 from separate experiments). (F) PKCz activity was assessed from cell ly
C2-Ceramide-treated cells with or without the PKCz inhibitor. #Corresponds to co
(G) Representative immunofluorescence of CD36 in H4IIe cells transfected w
C2-Ceramide.
(H) Circulating glucose levels measured during an insulin tolerance test (ITT) (0.75
ACPD. *Corresponds to comparison of WT to Alb or Art-AC. zCorresponds to com
Art-AC + ACPD.
(I) Biochemical quantification of hepatic lipid accumulation in Alb-AC or Art-ACm
by Student’s t test.
See also Figure S5.
CelDISCUSSION
Here, we report mouse models demonstrating inducible de-
creases of ceramide within the liver and adipose. The use of an
adiponectin promoter-driven rtTA (Art) has allowed us to eval-
uate the adipocyte-specific contributions of sphingolipids to
whole-body metabolic dysfunction. Our inducible acid cerami-
dase model bypasses the compensatory mechanisms and
developmental issues present in constitutive models and gives
us the opportunity to study acute modifications of ceramide-
induced metabolic dysfunction in adult mice. With this system,
we demonstrate that the acute depletion of ceramide in hepa-
tocytes or adipocytes of adult mice can prevent and reverse
the development of hepatic steatosis while simultaneously
improving systemic glucose tolerance and insulin sensitivity in
adult mice with diet-induced obesity. These studies highlight
the prominent cross-talk between the liver and adipose tissue
that allows for equilibration of sphingolipids between the two
tissues. Furthermore, these studies define a causal role for
ceramide in the pathogenesis of diet-induced NAFLD.
We found that that C16:0 and C18:0 ceramide levels to be 50%
of WT in Alb-AC mice livers, indicating that the hepatic accumu-
lation of particular ceramide subspecies more prominently
contributes to the development of NAFLD and systemic insulin
resistance. Consistent with our findings, recent work has shown
that mice with ceramide synthase 6 deficiency (cerS6D/D) exhibit
reduced C16:0 ceramide levels and are protected from HFD-
induced obesity and glucose intolerance (Turpin et al., 2014).
By contrast, heterozygous deletion of ceramide synthase 2
promotes a paradoxical increase in C16:0 ceramides to confer
greater susceptibility to diet-induced insulin resistance (Raichur
et al., 2014). Importantly, we also observed that concurrent with
the lowering of hepatic ceramides, hepatic DAG levels were
increased in our Alb-AC mice to almost double of those
measured in WT mice. In line with several studies, these findings
further question the role of liver DAGs as a causative agent of he-
patic steatosis and insulin resistance (Brown et al., 2010; Farese
et al., 2012; Minehira et al., 2008; Monetti et al., 2007; Voshol
et al., 2003). Nonetheless, this does not rule out the possibility
that a particular DAG subspecies (i.e., sn-1,2-diacylglyerols) is
able to induce hepatic steatosis and insulin resistance under
certain conditions (Boni and Rando, 1985). Thus, these studies
directly link excess accumulation of hepatic ceramide to the
development of non-alcoholic fatty liver disease and systemic
insulin resistance in rodents.
Elevated circulating ceramides are observed in patients with
type 2 diabetes and these levels correlate with the severity ofwere treated with C2-ceramide (100 mM, in 0.2% BSA) or BSA for 1 hr prior to
r was included for 90 min prior to ceramide treatments in non-transfected cells
sates harvested from cells represented in (D). zCorresponds to comparison of
mparison of BS-treated cells that was transfected with either GFP or caPKCz.
ith GFP, dnPKCz, or caPKCz. Each group is treated with either DMSO or
U/kg) of Alb-AC or Art-AC mice and littermate controls after daily injections of
parison of WT andWT + ACPD. #Corresponds to comparison of WT and Alb or
ice and littermate controls after daily injections of ACPD. *z#p < 0.05, **p < 0.01
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insulin resistance (Boon et al., 2013; Haus et al., 2009; Lopez
et al., 2013). Whether plasma ceramides are a contributor or
merely a marker of systemic insulin resistance has been unre-
solved.We show that when ceramide species are acutely broken
down in liver and adipose of obese mice, there is also a corre-
sponding significant lowering of plasma ceramides. Thus, our
current findings not only suggest that the liver can be a major
contributor of circulating ceramide species, but also reveal that
the adipocyte may also contribute substantially to changes in
serum ceramides. While it appears likely that these two tissues
shuttle a common pool of sphingolipids back and forth through
the circulation, it remains uncertain if the adipose supplies the
liver with ceramides- where they can be repackaged into lipopro-
tein particles. Alternatively, each of these tissuesmay function as
a sink whereby excess circulating ceramides may be taken up
from the circulation for storage or metabolism. Furthermore,
these findings point to the notion that plasma ceramide levels
reflect changes in hepatic ceramide levels and are valuable
markers of hepatic metabolic health.
The roles of atypical PKCs as mediators of ceramide-induced
insulin resistance have been previously reported. In particular,
C16 ceramides are potent activators of PKCz activity in vitro
(Mu¨ller et al., 1995). Specifically, in cultured muscle cell lines,
PKCz can phosphorylate the plextrin homology domain of Akt
on threonine residue 34 (Powell et al., 2003). This phosphoryla-
tion site alters the affinity for Akt to 3,4,5-trisphosphate, thus
interfering with Akt translocation to plasma membrane microdo-
mains where it is activated (Fox et al., 2007). A recent report by
the Farese group suggests that aberrant activation of atypical
PKC, is evident in livers of Lepob/ob mice and is essential for
impairments in Akt-mediated signaling to FoxO1; this is rescued
in vivo by pharmacological inhibition of atypical PKCs (Sajan
et al., 2015). PKCz has also attracted attention for its role in lipid
homeostasis, particularly as a mediator of SREBP-1c driven
lipogenesis (Sajan et al., 2004, 2009; Taniguchi et al., 2006).
Moreover, PKCz has also been previously noted to play a facili-
tative role in CD36 activation to promote lipid uptake into cardi-
omyocytes (Luiken et al., 2009). We show here that targeted
manipulation of ceramide alters atypical PKC activation in the
liver. As such, our data support the notion that ceramides may
be a causal effector of selective insulin resistance by driving
atypical PKC activation and associated lipogenic and lipid up-
take processes, while simultaneously impairing Akt-mediated
regulation of hepatic glucose output. The contribution of sphin-
goid bases to this process is intriguing, as sphingosine can stim-
ulate or suppress PKCz activation, depending on the dosage
(Mu¨ller et al., 1995). Here, we note the potential of sphingosine
to impair the activation of aPKC and prevent lipid uptake. The
rapid release of sphingosine from the adipocyte into the portal
circulation for delivery to the liver may explain how adipose-
specific ceramidase activation exerts more rapid beneficial
effects on the liver.
Collectively, our data suggest that the accumulation of ce-
ramides is critical in the development of non-alcoholic fatty liver
disease and hepatic insulin resistance. Induction of AC activity
rescues existing hepatic steatosis and metabolic syndrome in
mice with diet-induced obesity, suggesting that it is a potential
therapeutic target. Strategies for AC enzyme replacement have
been under development for the treatment of Farber disease276 Cell Metabolism 22, 266–278, August 4, 2015 ª2015 Elsevier Inc(AC deficiency) (Schuchman and Galanin, 2014), and this may
provide additional benefits in the form of systemic metabolic
improvements. Past clinical data have shown that serum adipo-
nectin levels inversely correlate with hepatic triglyceride con-
tent (Turer et al., 2012). Considering that adiponectin’s main
target tissue is the liver and it is known to confer ceram-
idase activity through its receptors AdipoR1 and R2, we expect
adiponectin to exert similar effects as seen for our acid ceram-
idase transgene, such as reducing hepatic triglyceride accumu-
lation and improving hepatic insulin sensitivity (Holland et al.,
2011).
EXPERIMENTAL PROCEDURES
Animals
All animal experimental protocols were approved by the Institutional Animal
Care and Use Committee of University of Texas Southwestern Medical Center
at Dallas. TRE-ACmice were generated by subcloning themouse AC gene into
a plasmid containing the TetO element. Following linearization, the construct
was injected into C57/Bl6-derived blastocysts. Transgene-positive offspring
were genotyped using PCRwith the following primer sets: TRE-AC, 50-GACTG
TATTCACAACCTTGATG, and 50-CATCTTCCCATTCTAAACAAC.
The Rosa26-loxP-stop-loxP-rtTA and Albumin-Cre mice were lines were
obtained from Jackson Laboratories. Albumin-Cre mice were bred with
the Rosa26-loxP-stop-loxP-rtTA mice to achieve liver-specific expression of
rtTA. This mouse was subsequently crossed to the TRE-AC transgenic mice.
The resulting triple transgenic mice expressed AC in liver only after exposure
to doxycycline (Dox). A transgenic mouse was generated using a 5.4 kB adipo-
nectin promoter fragment driving the expression of rtTA exclusively in adipo-
cytes. All overexpression experiments were performed in a pure C57/Bl6
background. All experiments were conducted using littermate-controlled
male mice. All Dox-chow diet (200 mg/kg Dox) or HFD-Dox (200 mg/kg Dox)
experiments were initiated at 6–16 weeks of age.
Acid Ceramidase Activity Assay
Acid ceramidase activity was determined by a fluorimetric assay using the
substrate Rbm 14-12, a synthetic ceramide analog that possess a 12-carbon
fatty acid chain length, at 20 mM after incubation for 3 hr with tissue lysates
(20 mg protein) of both wild-type mice (WT) and Alb-AC mice after 8 weeks
of HFD-dox (Bedia et al., 2010).
Lipid Quantifications
Sphingolipids were quantified as described previously by liquid chromatog-
raphy-electrospray ionization-tandem mass spectrometry (LC/ESI/MS/MS)
using a Shimadzu Nexera X2 UHPLC system coupled to a Shimadzu LCMS-
8050 triple quadrupole mass spectrometer (Holland et al., 2011). Diacylgly-
cerol and C17 FFA were quantified using an ABI 5600+ (AB Sciex) following
direct infusion of extracted lipids containing 18 mM ammonium fluoride to
aid in ionization of neutrals and to reduce salt adducts. Data from the AB Sciex
5600+ was collected and calibrated with Analyst and PeakView Software (AB
Sciex). Lipid species were identified based on exact mass and fragmentation
patterns and verified by lipid standards.
Streptozotocin Administration
Micewere fasted for 6 hr and subjected to a single intraperitoneal (i.p.) injection
of streptozotocin (STZ) (Sigma #S1030) at the dose of 135 mg/g body weight.
STZ was stored at20C as powder and freshly diluted in ice-cold sodium cit-
rate buffer (0.1 M, pH 4.5) before injection as previously described (Ye et al.,
2014).
aPKC Inhibitor
Inhibitor of aPKCs, PKCi and PKCz, 2-acetyl-1,3-cyclopentanedione (ACPD),
was purchased from Sigma. Its specificity was reported previously (Sajan
et al., 2014a). In addition, we presently found that ACPD did not inhibit
kinases, Akt2, FGFR1/2/3/4, mTOR, GSK3b, IRAK1/4, JAK1/2, MEK1,
ERK1/2, JNK1/2, PKA, Src, ROCK2, ROS1, or PI3Ka/a, as tested by Life.
Technologies. Alb-AC and WT controls were injected subcutaneously
daily with ACPD (10 mg/kg) in PBS or PBS only for 1 month. Art-AC and
WT controls were injected subcutaneously daily with ACPD (10 mg/kg) in
PBS or PBS only for 3 days.
Cell Culture
H4IIe rat hepatoma cells were cultured in low glucose DMEM supplemented
with 10% fetal bovine serum. Dominant-negative PKCz (Soh and Weinstein,
2003) and caPKCz (Chou et al., 1998) were purchased from Addgene and
transfections were performed with Lipofectamine 3000 (Invitrogen) according
to the manufacturer’s instructions.
Statistics
All results are provided as means ± SEM. All statistical analyses were
performed using GraphPad Prism. Differences between the two groups
over time (indicated in the relevant figure legends) were determined by a
two-way ANOVA for repeated-measures. For comparisons between two
independent groups, a Student’s t test was used. Significance was accepted
at p < 0.05.
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